Patients with Multiple Sclerosis (MS) will have routine access to a drug that can slow disability under a deal struck between NHS England and the manufacturer Roche, paving the way for its approval by NICE. Ocrelizumab (also known as Ocrevus) is the first treatment that can modify or change the course of the disease to […]
Bringing together skills, expertise and shared knowledge in ambulance services
